hERG Inhibitors with Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment
- 7 October 2013
- journal article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 25 (2) , 197-207
Abstract
Drug Mode of Action and hERG‐Related Safety: Introduction: Since the discovery of the link that exists between drug‐induced hERG inhibition and Torsade de Pointes (TdP), extreme attention has been given to avoid new drugs inhibiting this channel. hERG inhibition is routinely screened for in new drugs and, typically, IC50 values are compared to projected plasma concentrations to define a safety margin.Methods and Results: We aimed to show that drugs with similar hERG potency are not uniformly pro‐arrhythmic—this depends on the drug binding kinetics and mode of action (trapped or not) rather than the IC50 value only. We used a mathematical model of hERG and its related encoded current IKr to simulate drug binding in different configurations. Expression systems mimicking the screening process were first investigated. hERG model was then incorporated into a canine action potential (AP) and tissue model to study the impact of drug binding configurations on AP and pseudo‐ECG (QT interval prolongation). Our data show that: (1) trapped and not trapped configurations and different binding kinetics could be identified during hERG screening; (2) slow binding, not trapped drugs, induced less AP prolongation and minimal QT interval prolongation (4.7%) at a concentration equal to the IC50 whereas maximal pro‐arrhythmic risk was observed for trapped drugs at the same concentration (QT interval prolongation, 23.1%).Conclusion: Our study demonstrates the need for screening for hERG binding configurations rather than potency alone. It also demonstrates the potential link between hERG, drug mode of action and TdP, and the need to question the current regulatory guidance.Keywords
Funding Information
- AstraZeneca UK
This publication has 27 references indexed in Scilit:
- Automated electrophysiology makes the pace for cardiac ion channel safety screeningFrontiers in Pharmacology, 2011
- Reducing QT liability and proarrhythmic risk in drug discovery and developmentBritish Journal of Pharmacology, 2010
- hERG Potassium Channels and the Structural Basis of Drug-Induced ArrhythmiasChemical Research in Toxicology, 2008
- Assessment of QT liabilities in drug developmentCell Biology and Toxicology, 2006
- Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (IKr) ChannelJournal of Cardiovascular Electrophysiology, 2004
- The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel BlockJournal of Cardiovascular Pharmacology, 2004
- Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovascular Research, 2003
- Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actionsAmerican Journal of Gastroenterology, 2001
- Evaluation of Drug-Induced QT Interval ProlongationDrug Safety, 2001
- Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastineThe American Journal of Cardiology, 1994